Tinova Immune Therapeutics

Tinova Immune Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation T-cell receptor (TCR) T-cell therapies for solid tumors. The company leverages its proprietary platform to identify high-affinity TCRs and optimize T-cell fitness to overcome the immunosuppressive microenvironment of tumors. Tinova's lead program, TN-101, is a TCR-T therapy targeting the NY-ESO-1 antigen and is currently in Phase 1 clinical trials. The company aims to provide curative options for patients with advanced malignancies by targeting intracellular tumor-specific antigens. Headquartered in Suzhou, China, Tinova is supported by leading venture capital firms and maintains state-of-the-art R&D and manufacturing facilities.